Skip to main content
. 2022 Oct 11;20:464. doi: 10.1186/s12967-022-03679-y

Table 2.

Uni- and multivariate prognostic analyses for DFS

Variables Univariate Multivariate
N HR [95% CI] p-value N HR [95% CI] p-value
Patient's age 303 1.00 [0.99–1.01] 0.839
Gender, male vs. female 303 1.04 [0.73–1.48] 0.831
Tumor site, head and neck vs. extremity 382 0.00 [0.00- Inf] 0.118
Tumor site, internal trunk vs. extremity 1.28 [0.90–1.81]
Tumor site, superficial trunk vs. extremity 0.68 [0.40–1.16]
Tumor depth, superficial vs. deep 128 0.26 [0.06–1.07] 0.062
Pathological type, leiomyosarcoma vs. UPS 610 2.42 [1.65–3.54] 2.06E−05 55 3.63 [0.28–46.61] 0.322
Pathological type, liposarcoma vs. UPS 1.44 [1.00–2.06] 55 1.97 [0.10–37.16] 0.650
Pathological type, myxofibrosarcoma vs. UPS 1.01 [0.51–2.01] 55 7.02 [0.33–150.7] 0.213
Pathological type, other vs. UPS 0.78 [0.35–1.72] 55 0 [0.00—Inf] 0.999
Pathological tumor size (cm) 142 1.05 [1.02–1.09] 1.39E−03 55 1.07 [0.98–1.17] 0.155
Pathological FNCLCC grade, 3 vs. 1–2 239 1.47 [0.93–2.33] 0.098 55 6.84 [1.04–44.8] 0.045
Genetic profile, complex vs. simple 598 1.17 [0.89–1.54] 0.270
CINSARC, high-risk vs. low-risk 610 2.22 [1.70–2.90] 4.35E−09 55 1.14 [0.26–4.93] 0,865
CSPG4, high vs. low 610 1.49 [1.14–1.94] 3.36E−03 55 10.47 [1.04–105.3] 4.62E−02

The significant p-values are in bold

UPS Undifferentiated Pleomorphic Sarcoma, FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer